Latest from Johns Hopkins Cancer Center

Jean Wright, MD, discusses the evolution of radiation oncology in early-stage breast cancer and how novel radiation modalities are poised to transform the field.
Emmanuel S. Antonarakis, MBBCh, professor of oncology, Johns Hopkins Medicine, discusses a phase II trial evaluating the combination of sipuleucel-T (Provenge) plus radium-223 dichloride (Xofigo) versus sipuleucel-T alone in patients with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC).
Combination therapy with radium-223 and sipuleucel-T yielded conflicting results in patients with metastatic castration-resistant prostate cancer.
Benjamin P. Levy, MD, assistant professor of oncology and clinical director of Medical Oncology, Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses ongoing research regarding the use of liquid biopsies in lung cancer.
Benjamin P. Levy, MD, discusses the next steps with liquid biopsies in non–small cell lung cancer and its broader use in oncology.
Benjamin P. Levy, MD, discusses biomarkers for immunotherapy in lung cancer.
Ramy Sedhom, MD, looks back on his first year of oncology fellowship and shares advice for first-year fellows and trainees.
Research into the mechanisms  that promote resistance to immune checkpoint blockade therapies suggests the need for new strategies for patients with immunorefractory disease. 
Publication Bottom Border
Border Publication
x